• 제목/요약/키워드: drug use review (DUR)

검색결과 21건 처리시간 0.021초

의약품의 적정 사용을 위한 전략 (Strategies to Improve Use of Medicines)

  • 박실비아
    • 한국의료질향상학회지
    • /
    • 제12권2호
    • /
    • pp.93-112
    • /
    • 2006
  • This study reviewed published studies on interventions used by hospitals, health insurance programs, or governments to improve use of medicines in foreign countries. Interventions to improve use of medicines are classified into two categories: 1) information strategies-dissemination of educational materials, group education, one-to-one educational outreach, drug utilization review, and feedback; 2) managerial strategies- formularies, prior authorization, and financial incentives. Dissemination of educational materials, which is a common intervention, was unsuccessful in changing physicians' prescribing behaviors. Problem-based small group education was more likely to change behaviors than didactic large group education. One-to-one educational outreach(academic detailing) was among the most effective strategies used to change prescribing behaviors. Prospective drug utilization review (DUR) program was more successful in improving use of medicines than retrospective DUR program. Feedback intervention has been reported to be ineffective to change behaviors. Formularies are frequently used to control medication use by most health insurance programs. Financial incentives provide physicians economic incentives according to appropriateness of prescribing. However, few published studies have assessed the efficacy of formularies or financial incentives. Prior authorization requires physicians to get authorization from health insurers before prescribing a certain group of drugs which is usually of high costs or risk. There is no magic bullet for quality use of medicines. Multifaceted interventions that help to predispose, enable, and reinforce desired behaviors are more likely to be successful.

  • PDF

졸피뎀의 체계적 관리 방안 연구 (A Study on the Systematic Management of Zolpidem)

  • 정수철
    • 한국콘텐츠학회논문지
    • /
    • 제20권2호
    • /
    • pp.462-471
    • /
    • 2020
  • 일반적으로 수면제로 사용되는 졸피뎀은 신경 억제 물질을 증가시키기 위해 GABA 수용체에 결합한다. 실제 졸피뎀을 4주 이상 연속으로 복용하는 경우는 많이 있다. 현재 한국에서 시행되고 있는 의약품 사용평가(DUR)은 졸피뎀의 사용 패턴을 확인할 수 있다. 수면제인 졸피뎀의 과다 사용을 예방 할 필요가 있다. 본 연구는 2019년 5월 10일부터 2019년 5월 15일까지 진행되었다. 검색된 총 125,197건의 문서 중 1차 및 2차 선별을 실시하여 진행하였다. 졸피뎀 과다 사용과 직접적인 관련이 있는 최종 254개의 문헌 사례를 선정하였다. 체계적인 문헌 연구를 통해 졸피뎀의 과다 사용을 예방 할 수 있는 방안을 모색하고자 하였다. 연구대상 선별과정에서 연구의 비뚤림 효과를 최소화 하였다. 졸피뎀의 과다 사용은 심각했으며 사용량이 계속 증가하는 추세였다. 졸피뎀을 이용한 범죄도 증가하고 있었다. 졸피뎀은 마약류 통합 관리 시스템과 의약품 사용평가를 통해 관리 될 수 있다고 연구되었다. 졸피뎀의 사용을 줄이기 위해서는 마약류 통합관리 시스템과 과다 사용자 교육을 통한 수요와 공급을 동시에 억제할 필요가 있다.

국내 건강보험심사청구자료에 근거한 다빈도 치료중복 의약품 약효군 분석 (Analysis of Frequent Therapeutic Duplication Drug Classes Based on National Health Insurance Claimed Data in Korea)

  • 손현순;이영숙;최경업;신현택
    • 한국임상약학회지
    • /
    • 제20권3호
    • /
    • pp.262-267
    • /
    • 2010
  • Therapeutic duplication of prescriptions is the most frequently reported inappropriate drug use in Korea. To prevent significant problems during drug prescribing and dispensing, prospectively, development of standard including drug lists considered as therapeutic duplications for the prioritized drug classes first would be necessary. This study was aimed to analyze frequent drug classes of therapeutic duplications by healthcare providers in clinical practice settings. National health claims data for drug review and reimbursement (1,426,065 prescriptions dated March 19, 2008) were analyzed. Therapeutic duplication was defined as the prescription including more than 2 ingredients belonging to the same KFDA drug classification numbers that considered to have therapeutic similarities. The following 3 drug classes were mostly frequent therapeutic duplication classes: 114 anti-pyretics, analgesics and anti-inflammatory drugs; 117 drugs for psycho-nervous system; 141 Antihistamines. About 3.5% of overall prescriptions analyzed showed therapeutic duplications. This result might be starting step to develop DUR therapeutic duplication standard.

한국과 미국의 약사 연수 교육 분석을 통한 자기 주도적 약사 연수 교육 도입 방안 (A Study on the Introduction of Self-directed Pharmaceutical Training Education through the Analysis of Pharmaceutical Education in Korea and the U.S.)

  • 정수철
    • 한국콘텐츠학회논문지
    • /
    • 제19권1호
    • /
    • pp.598-607
    • /
    • 2019
  • 현재 한국의 약사 연수 교육은 연간 8시간으로 대한약사회와 그 산하 지부 및 분회에서 주로 실시하고 있다. 정해진 시간에 다수의 약사들을 대상으로 진행되는 교육은 학습효과가 제한적이며 적극적인 학습 참여를 유도하기 어렵다. 본 연구에서는 약사 제도의 역사가 긴 미국의 약사 연수 교육을 문헌 연구 하여 한국의 약사 연수 교육의 발전 방안을 찾아보았다. 연구의 대상은 한국과 미국의 약사 연수 교육 운용 방식, 평가제도, 교과목 등이었다. 연구 결과 미국의 약사연수 교육은 다양한 방식이었으며 이수 시간이 길며 약사 면허 갱신 제도와 연계되어 있었다. 한국의 약사 연수 교육이 교육 시간의 연장, 교육 내용의 다양화, 자기 주도적 학습 및 현장 실습 교육을 도입 한다면 현재보다 더 발전할 것이다.

이비인후과 영역에서 일반의와 전문의에 의한 외래처방전의 비교 평가 (Comparative Evaluation of Drug Use for Outpatients Prescribed by General Practitioner and Specialized Practitioner in ENT Area)

  • 민현성;송태범;이명구;장제관;이종길;임성실
    • 약학회지
    • /
    • 제54권4호
    • /
    • pp.258-269
    • /
    • 2010
  • As people are easy to access the National Health Insurance, medical health service has been increased. It contributed to extend human's average life expectancy and to get better health care. But also increased unnecessary health service or inappropriate drug use. Therefore, DUR (Drug Use Review) is needed to induce appropriate drug use. The purpose of this study is to evaluate outpatient prescriptions by General Practitioner (GP) and Specialized Practitioner, especially indication for ENT referral including common cold which is the frequent indications that have patient see doctor. This study was reviewed retrospectively prescriptions for ENT referral collected at the A pharmacy for ENT Clinic in Cheong-Ju, B pharmacy for GP Clinic in BoEun from Feb 2nd, 2009 to Feb 28th, 2009. Each pharmacy located closed to the each enrolled clinic. The numbers of collected prescriptions were each A pharmacy (n=2501), B pharmacy (n=1343). This study was classified Drug Related Problems (DRPs) those prescriptions had as total 6 groups according to following 6 categories; 1) Unnecessary Drug, 2) Wrong Drug, 3) Low Dose, 4) Overdose, 5) Wrong Instruction, 6) Wrong Combination. In results, Specialized Practitioner's prescriptions had more DRPs than General Practitioner's prescriptions (ENT 155.34% vs GP 130.01%). In detail, Specialized Practitioner's prescriptions had more DRPs in Low Dose (ENT 16.95% vs GP 4.77%), Overdose (ENT 6.72% vs G.P 5.51%), Wrong Instruction (ENT 7.91% vs GP 5.81%), Wrong Combination (ENT 29.31% vs GP 25.09%). These DRPs would be caused from lack of consideration for dosage and drug interaction. General Practitioner's prescriptions had more DRPs in Unnecessary Drug (ENT 70.37% vs GP 78.85%), Wrong drug (ENT 4.12% vs GP 9.98%). These DRPs would be associated with drug selection. This study was assumed that Specialized Practitioner is better prescriber than General Practitioner because Specialized Practitioner complete additional intern and residency training. But, Specialized Practitioner is not always better prescriber than General Practitioner. Furthermore, prescriptions of both Specialized Practitioner and General Practitioner had many problems. In conclusion, It could be cut down the excessive medical expense and expected more efficient medical care by reducing DRPs, thus contributing to the improvement of national health. In order to pharmacist must have good professional ability of pharmacotherapy to help the physician for the drug selection.

다처방에 의한 의약품의 병용으로 인한 중복 및 병용금기의 문제: 고양시 및 제주도 DUR 시범사업을 중심으로 (Concomitant Medication by Multiple Prescriptions Causing Duplication and Severe drug Interaction: During DUR Pilot Projects in Goyangsi and Jejudo)

  • 신광식
    • 한국임상약학회지
    • /
    • 제21권2호
    • /
    • pp.106-114
    • /
    • 2011
  • 1) 제주도 사업의 경우에 고양시보다 의료기관의 참여도가 높았는데 이것은 처방내에서 혹은 동일 의사의 처방내에서 병용금기나 중복의 발생을 줄이는 노력을 기울인 사실을 의미하였다. 빈도수에 있어서 병용금기는 고양시에서 처방전 1만 건당 0.45건 발생에서 제주도는 0건으로, 중복의 경우는 고양시에서 1만 건당 197건에서 제주도는 23건으로 감소하였다. 2) 하지만 제주도의 의료기관 참여도가 높음에도 불구하고 다른 의사 처방과의 점검에서는 병용금기 및 중복이 뚜렷이 감소하지 않았다. 병용금기의 발생은 고양시에서 1만 건당 4.95건에서 제주도의 경우 4.16건으로, 중복의 경우에 고양시의 경우 1만 건당 426건에서 제주도는 381건으로 감소하였지만 그 차이는 동일 의사 점검에서와 같은 뚜렷한 감소가 아닌 미세한 것이었다. 3) 두 지역을 통합하여 계산하였을 때 병용금기 발생의 동일 의사 점검: 다른 의사 점검의 비(比)(ratio)는 1:23으로 계산되었다. 4) 고양시 지역에서 중복의 발생은 동일 의사 점검: 다른 의사 점검의 비(比)(ratio)는 1: 2.12이었으며 제주도의 경우 그 비(比)(ratio)는 1:16.5이다. 5) 병용금기나 중복의 발생 문제 대부분이 다른 의사가 발행한 복수 처방에 의한 의약품의 병용에서 비롯하는 문제이며 이것은 의도하거나 인지하지 못한다는 점에서 단순 다제병용보다 심각한 문제를 포함할 수 있다. 6) 연구의 발견점은 의료 및 약사용 측면에서 통합성을 높이는 정책대안의 시급성을 시사하고 있으며 DUR제도의 확대강화와 단골약국 이용을 통하여 이러한 목표를 향한 정책을 지지해주는 결과라고 볼 수 있다.

불안장애 환자에서의 치료약제 중복사용에 대한 후향적 의약품사용평가 연구 (Retrospective Drug Utilization Review Study on the Therapeutic Duplication in Patients with Anxiety Disorders)

  • 박찬현;손현순;신현택;최경업
    • 한국임상약학회지
    • /
    • 제20권1호
    • /
    • pp.39-49
    • /
    • 2010
  • The present study was aimed to examine the occurrence and influencing factors therapeutic duplication (TD) of medications for anxiety disorders by analyzing the relevant prescription data. In this study, the prescription data issued on March 19, 2008 in domestic medical institutes were utilized. TD was defined as more than two medications under the same therapeutic classification per prescription based on the Anatomical Therapeutic Classification (ATC) code. The assessment of TD was performed based on the number of cases and on the ratio determined. To identify the influencing factor of TD, the variables related to the differences in the TD ratio were analyzed based on the results of the Chi-Square test conducted with the variables; patients, medical institutes, diseases, and treatments. The number and ratio of TD were determined to be 1,333 out of the total of 19,219 anxiety disorder cases, and 6.94%, most cases involving benzodiazepine derivatives, respectively. The TD ratio was found to be higher in relation to males than to females. Patients with national health insurance benefits have a higher TD ratio compared to the medical-aid beneficiaries. The TD ratios were highest in clinics, psychiatry divisions, and Gyeongsang district. The TD ratio of the cases with more than two anxiety disorders was found to be higher than that of the cases with only one anxiety disorder. As the number of medications per prescription increased, the TD ratio was shown to have become gradually higher. In conclusion, in order to prevent TD, the concurrent DUR system should be implemented. The prescribers and pharmacists must be educated regarding duplicated medications to promote the safe and effective use of medicines, without unnecessary TD.

정신신경용계 의약품의 치료군 중복처방 평가기준(안) 개발 (Development of Criteria for Therapeutic Duplications of Psycho-Nervous System Drugs)

  • 손현순;최윤영;이영숙;최경업;신현택
    • 약학회지
    • /
    • 제55권3호
    • /
    • pp.185-194
    • /
    • 2011
  • Therapeutic duplication (TD) is frequently reported inappropriate drug use in healthcare settings in Korea. This study was aimed to develop TD criteria for psycho-nervous system drugs (KFDA classification 117 and 119). ATC classification was used to determine therapeutic and/or chemical similarities among the 93 ingredients reviewed. Clinical practice guidelines, textbooks and product labels were referenced for principles and evidences of possible drug combination usage. 16 groups that listed ingredients to be considered as TD were established and the criteria would be helpful to prevent TDs.

당뇨병환자에게 부적절하게 사용된 Metformin의 처방빈도 분석 (Frequency of Inappropriate Metformin Use in Patients with Diabetes Mellitus)

  • 신혜연;정기화
    • 약학회지
    • /
    • 제54권6호
    • /
    • pp.455-460
    • /
    • 2010
  • We evaluated the inappropriateness of metformin use in patients with type 2 diabetes and chronic medical conditions to identify the frequency of the prescription metformin in violation of the food and drug administration (FDA) black box warning. We reviewed medical records of 307 outpatients who received metformin at endocrinology department in a hospital setting between January 1, 2005 and August 30, 2009. Of the 307 outpatients, 25 discontinued treatment of metformin due to elevated serum creatinine level (Scr${\geq}$1.5 mg/dl in male, Scr${\geq}$1.4 mg/dl in female), cancers, and/or liver disease. 5 were lost to follow-up. 89 (29.0%) of the patients had cardiovascular disease, 54.1% for hypertension, 9.8% for liver disease, and 60 (20.8%) for chronic kidney disease. 12 patients (3.9%) with chronic kidney disease and/or elevated serum creatinine level, and 1 patient (0.3%) with lactic acidosis were contraindicated to metformin use. Metformin should be avoided in 7 outpatients (2.3%) with active hepatitis and 1 patient (2.6%) with liver cirrhosis. Of the 307 outpatients, 13 (4.2%) patients who received metformin at the first visit and 16 (8.7%) patients who received metformin at the last visit violated to black box warning. 8 (2.6%) of the patients were in precautionary conditions to metformin use. Adjusted mean difference of serum creatinine was -0.16 mg/dl [95% CI: -0.22 to -0.11 (p<0.05)] and adjusted mean difference of alanine aminotransferase was 4.46 IU/l [95% CI: 2.47 to 6.44 (p<0.05)] between the first visit and the last visit. Critical number of elderly patients who are at the high risks of drug-disease and drug-laboratory interaction is exposed to the inappropriate metformin use in violation of black box warning. The periodic evaluation of metformin use and monitoring prescription through drug utility review (DUR) system is needed to improve patients' safety and to reduce adverse drug events.

호흡기계 작용 약물의 치료군 중복처방 평가기준 개발 (Therapeutic Duplication Criteria Development of Respiratory System Drugs)

  • 최경업;손현순;김남효;신현택;이영숙
    • 약학회지
    • /
    • 제56권2호
    • /
    • pp.126-135
    • /
    • 2012
  • Purpose: To develop therapeutic duplication criteria for the drugs used for respiratory diseases. Method: Therapeutic duplication was defined as "more than 2 drug ingredient-usage in which each has the same therapeutic effect and combination therapy does not confer additional therapeutic benefit". Respiratory system drugs approved in Korea were examined for the study. The WHO's Anatomical Therapeutic Chemical Classification System was used for grouping of the corresponding drug ingredients. The principles and recommendations on combination usage or multiple drug regimens were reviewed by using the clinical practice guidelines, textbooks, product labelings, and clinical articles. Clinical expert group consultation was performed and expert opinions were incorporated into the final criteria. Results: Nine hundred sixty two drug products with Korean Food and Drug Administration classification codes of 141, 149, 222, and 229 were evaluated, of which 87 active ingredients were composed. The drug ingredients were classified into 12 groups (antihistamines, oral nasal decongestants, leukotriene receptor antagonists, inhaled anticholinergics, inhaled corticosteroids, oral ${\beta}2$-agonists, long-acting ${\beta}2$-agonists, short-acting ${\beta}2$-agonists, xanthines, antiallergics, mucolytics and cough suppressants). The use of more than 2 drug ingredients including the same group was therapeutic duplication, and thus combination should be recommended not to be used. Conclusion: Twelve drug groups were identified as therapeutic duplication criteria. Combination therapy within each group should not be used otherwise therapeutic benefits outweigh potential risks.